Human osteopontin: Potential clinical applications in cancer (Review)

International Journal of Molecular Medicine

Volumn 39, Issue 6, 2017, Pages 1327-1337

  Hao, Chengcheng ^a,b   Cui, Yuxin ^c   Owen, Sionen ^c   Li, Wenbin ^b   Cheng, Shan ^a,b   Jiang, Wen G ^a,b,c  

^a Department of Biochemistry and Molecular Biology ^*  (United Kingdom)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cancer; Disease progress; Osteopontin; Splice variants

Indexed keywords

OSTEOPONTIN; TUMOR MARKER; ISOPROTEIN; SPP1 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; BLADDER CANCER; BREAST CANCER; COLORECTAL CANCER; DRUG TARGETING; ESOPHAGUS CANCER; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASM; MELANOMA; MOUTH SQUAMOUS CELL CARCINOMA; NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; REVIEW; SOFT TISSUE SARCOMA; STOMACH CANCER; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME; ANIMAL; DISEASE EXACERBATION; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; OSTEOPONTIN; POLYMORPHISM, GENETIC; PROTEIN ISOFORMS;

EID: 85019594992     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2017.2964     Document Type: Review

References (104)

1. Giachelli CM, Liaw L, Murry CE, Schwartz SM and Almeida M: Osteopontin expression in cardiovascular diseases. Ann NY Acad Sci 760: 109-126, 1995
2. Weber GF and Cantor H: The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev 7: 241-248, 1996
3. Denhardt DT and Noda M: Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 30-31 (30-31): 92-102, 1998
4. Sodek J, Ganss B and McKee MD: Osteopontin. Crit Rev Oral Biol Med 11: 279-303, 2000
5. Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT and Sørensen ES: Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 282: 19463-19472, 2007
6. Christensen B, Nielsen MS, Haselmann KF, Petersen TE and Sørensen ES: Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390: 285-292, 2005
7. Christensen B, Petersen TE and Sørensen ES: Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 411: 53-61, 2008
8. Denhardt DT and Guo X: Osteopontin: a protein with diverse functions. FASEB J 7: 1475-1482, 1993
9. Cho HJ, Cho HJ and Kim HS: Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 11: 206-213, 2009
10. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF and Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10: 184-190, 2004
11. Rittling SR and Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 90: 1877-1881, 2004
12. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M and Rudland PS: The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17: 463-474, 2006
13. Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8: 212-226, 2008
14. Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytela R and Giachelli CM: Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem 271: 28485-28491, 1996
15. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y and Sheppard D: The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274: 36328-36334, 1999
16. Scatena M, Liaw L and Giachelli CM: Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27: 2302-2309, 2007
17. Sun BS, Li Y, Zhang ZF, You J and Wang CL: Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg 96: 1943-1951, 2013
18. Gao YL, Xing LQ, Ren TJ, Hou JF, Xue Q, Liu C and Han YM: The expression of osteopontin in breast cancer tissue and its relationship with p21ras and CD44V6 expression. Eur J Gynaecol Oncol 37: 41-47, 2016
19. Yang L, Shang X, Zhao X, Lin Y and Liu J: Correlation study between OPN, CD44v6, MMP-9 and distant metastasis in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 26: 989-992, 2012 (In Chinese)
20. Kim JS, Bashir MM and Werth VP: Gottron's papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature. J Invest Dermatol 132: 1825-1832, 2012
21. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO, et al: Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169: 233-246, 2006
22. Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, et al: The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One 5: e9633, 2010
23. Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, Ohe Y, Tominaga S, Takagi Y, Sasaki S, et al: Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 57: 302-310, 2007
24. Wu CM, Chen PC, Li TM, Fong YC and Tang CH: Si-Wu-tang extract stimulates bone formation through PI3K/Akt/NF-κB signaling pathways in osteoblasts. BMC Complement Altern Med 13: 277, 2013
25. Wang Y, Yan W, Lu X, Qian C, Zhang J, Li P, Shi L, Zhao P, Fu Z, Pu P, et al: Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol 90: 642-648, 2011
26. Ogata T, Ueyama T, Nomura T, Asada S, Tagawa M, Nakamura T, Takahashi T, Matsubara H and Oh H: Osteopontin is a myosphere-derived secretory molecule that promotes angiogenic progenitor cell proliferation through the phosphoinositide 3-kinase/Akt pathway. Biochem Biophys Res Commun 359: 341-347, 2007
27. Chen RX, Xia YH, Xue TC, Zhang H and Ye SL: Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncol Rep 25: 803-808, 2011
28. Mi Z, Guo H, Wai PY, Gao C and Kuo PC: Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 27: 1134-1145, 2006
29. Tuck AB, Hota C and Chambers AF: Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 70: 197-204, 2001
30. Kerenidi T, Kazakou AP, Lada M, Tsilioni I, Daniil Z and Gourgoulianis KI: Clinical significance of circulating osteopontin levels in patients with lung cancer and correlation with VEGF and MMP-9. Cancer Invest 34: 385-392, 2016
31. Babarović E, Valković T, Budisavljević I, Balen I, Štifter S, Duletić-Načinović A, Lučin K and Jonjić N: The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma. Pathol Res Pract 212: 509-516, 2016
32. Lin Q, Guo L, Lin G, Chen Z, Chen T, Lin J, Zhang B and Gu X: Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer. Cancer Epidemiol 39: 539-544, 2015
33. Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, Dilana KD, Nasothimiou E, Harrington KJ, Polyzos A and Syrigos KN: The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 29: 1651-1657, 2009
34. Hsieh IS, Huang WH, Liou HC, Chuang WJ, Yang RS and Fu WM: Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol Pharmacol 83: 968-977, 2013
35. Anborgh PH, Caria LB, Chambers AF, Tuck AB, Stitt LW and Brackstone M: Role of plasma osteopontin as a biomarker in locally advanced breast cancer. Am J Transl Res 7: 723-732, 2015
36. Friedmann-Morvinski D, Bhargava V, Gupta S, Verma IM and Subramaniam S: Identification of therapeutic targets for glioblastoma by network analysis. Oncogene 35: 608-620, 2016
37. Güttler A, Giebler M, Cuno P, Wichmann H, Keßler J, Ostheimer C, Söling A, Strauss C, Illert J, Kappler M, et al: Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy. Radiother Oncol 108: 535-540, 2013
38. Etiz D, Ataizi FC, Bayman E, Akcay M, Acikalin MF, Colak E and Ciftci E: Prognostic value of osteopontin in patients treated with primary radiotherapy for head and neck cancer. Asian Pac J Cancer Prev 14: 5175-5178, 2013
39. Imano M, Satou T, Itoh T, Sakai K, Ishimaru E, Yasuda A, Peng YF, Shinkai M, Akai F, Yasuda T, et al: Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg 13: 1577-1582, 2009
40. Higashiyama M, Ito T, Tanaka E and Shimada Y: Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 14: 3419-3427, 2007
41. Ng L, Wan TM, Lam CS, Chow AK, Wong SK, Man JH, Li HS, Cheng NS, Pak RC, Cheung AH, et al: Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer. PLoS One 10: e0126219, 2015
42. Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, Yau TC, Lo O, Foo CC, Poon JT, et al: Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int 2015: 247892, 2015
43. Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM and Mulvihill SJ: Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 42: 193-197, 2013
44. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ and Goggins M: Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13: 487-491, 2004
45. Liu G, Fan X, Tang M, Chen R, Wang H, Jia R, Zhou X, Jing W, Wang H, Yang Y, et al: Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells. Cancer Lett 383: 171-182, 2016
46. Gimba ER and Tilli TM: Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett 331: 11-17, 2013
47. Salem M, Atti SA, Raziky ME, Darweesh SK and Sharkawy ME: Clinical significance of plasma osteopontin level as a biomarker of hepatocellular carcinoma. Gastroenterology Res 6: 191-199, 2013
48. Xu ST, Guo C, Ding X, Fan WJ, Zhang FH, Xu WL and Ma YC: Role of osteopontin in the regulation of human bladder cancer proliferation and migration in T24 cells. Mol Med Rep 11: 3701-3707, 2015
49. Moszynski R, Szubert S, Szpurek D, Michalak S and Sajdak S: Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynaecol Res 39: 1518-1525, 2013
50. Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M and Douchi T: Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res 32: 309-314, 2006
51. Subramani VN, Narasimhan M, Thiyagarajan M, Munuswamy BD and Jayamani L: Expression of osteopontin in oral squamous cell carcinoma and its surgical margins-an immunohistochemical study. J Clin Diagn Res 9: ZC66-ZC69, 2015
52. Kiss T, Ecsedi S, Vizkeleti L, Koroknai V, Emri G, Kovács N, Adany R and Balazs M: The role of osteopontin expression in melanoma progression. Tumour Biol 36: 7841-7847, 2015
53. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S and Donington JS: Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 28: 936-941, 2010
54. Zduniak K, Ziolkowski P, Ahlin C, Agrawal A, Agrawal S, Blomqvist C, Fjällskog ML and Weber GF: Nuclear osteopontin-c is a prognostic breast cancer marker. Br J Cancer 112: 729-738, 2015
55. Ortiz-Martínez F, Perez-Balaguer A, Ciprián D, Andrés L, Ponce J, Adrover E, Sánchez-Payá J, Aranda FI, Lerma E and Peiró G: Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. Hum Pathol 45: 504-512, 2014
56. Sun J, Feng A, Chen S, Zhang Y, Xie Q, Yang M, Shao Q, Liu J, Yang Q, Kong B, et al: Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1. Cell Mol Immunol 10: 176-182, 2013
57. Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, Yan S, Dong X, et al: Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer. Cancer Epidemiol 37: 985-992, 2013
58. Patani N, Jouhra F, Jiang W and Mokbel K: Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 28: 4105-4110, 2008
59. Sun SJ, Wu CC, Sheu GT, Chang HY, Chen MY, Lin YY, Chuang CY, Hsu SL and Chang JT: Integrin β3 and CD44 levels determine the effects of the OPN-A splicing variant on lung cancer cell growth. Oncotarget 7: 55572-55584, 2016
60. Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, Jin Y and Li W: Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol 137: 1061-1070, 2011
61. Blasberg JD, Goparaju CM, Pass HI and Donington JS: Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg 139: 1587-1593, 2010
62. Nakamura KD, Tilli TM, Wanderley JL, Palumbo A Jr, Mattos RM, Ferreira AC, Klumb CE, Nasciutti LE and Gimba ER: Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. Tumour Biol 37: 2655-2663, 2016
63. Tilli TM, Bellahcène A, Castronovo V and Gimba ER: Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines. BMC Cancer 14: 433, 2014
64. Tilli TM, Mello KD, Ferreira LB, Matos AR, Accioly MT, Faria PA, Bellahcène A, Castronovo V and Gimba ER: Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 72: 1688-1699, 2012
65. Lin J, Myers AL, Wang Z, Nancarrow DJ, Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang TD, et al: Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget 6: 22239-22257, 2015
66. Zhang MX, Xu YJ, Zhu MC and Yan F: Overexpressed ostepontin-c as a potential biomarker for esophageal squamous cell carcinoma. Asian Pac J Cancer Prev 14: 7315-7319, 2013
67. Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI and Kim KW: Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol 35: 1409-1416, 2009
68. Takafuji V, Forgues M, Unsworth E, Goldsmith P and Wang XW: An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26: 6361-6371, 2007
69. Tang X, Li J, Yu B, Su L, Yu Y, Yan M, Liu B and Zhu Z: Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int J Biol Sci 9: 55-66, 2013
70. Siddiqui AA, Jones E, Andrade D, Shah A, Kowalski TE, Loren DE, Chipitsyna G and Arafat HA: Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma. J Gastroenterol Hepatol 29: 1321-1327, 2014
71. Sarosiek K, Jones E, Chipitsyna G, Al-Zoubi M, Kang C, Saxena S, Gandhi AV, Sendiky J, Yeo CJ and Arafat HA: Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN. J Gastrointest Surg 19: 639-650, 2015
72. Ferreira LB, Eloy C, Pestana A, Lyra J, Moura M, Prazeres H, Tavares C, Sobrinho-Simões M, Gimba E and Soares P: Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma. Eur J Endocrinol 174: 551-561, 2016
73. Ferreira LB, Tavares C, Pestana A, Pereira CL, Eloy C, Pinto MT, Castro P, Batista R, Rios E, Sobrinho-Simões M, et al: Osteopontin-A splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget 7: 52003-52016, 2016
74. Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, Liu N, Fu Z, Kang C, Pu P, et al: Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro-oncol 12: 765-775, 2010
75. Hahnel A, Wichmann H, Greither T, Kappler M, Würl P, Kotzsch M, Taubert H, Vordermark D and Bache M: Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. BMC Cancer 12: 131, 2012
76. Inoue M and Shinohara ML: Intracellular osteopontin (iOPN) and immunity. Immunol Res 49: 160-172, 2011
77. Shinohara ML, Kim HJ, Kim JH, Garcia VA and Cantor H: Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc Natl Acad Sci USA 105: 7235-7239, 2008
78. Yushi Q, Li Z, Von Roemeling CA, Doeppler H, Marlow LA, Kim BY, Radisky DC, Storz P, Copland JA and Tun HW: Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma. Oncotarget 7: 32156-32171, 2016
79. Zohar R, Lee W, Arora P, Cheifetz S, McCulloch C and Sodek J: Single cell analysis of intracellular osteopontin in osteogenic cultures of fetal rat calvarial cells. J Cell Physiol 170: 88-100, 1997
80. Zhao W, Wang L, Zhang L, Yuan C, Kuo PC and Gao C: Differential expression of intracellular and secreted osteopontin isoforms by murine macrophages in response to toll-like receptor agonists. J Biol Chem 285: 20452-20461, 2010
81. Junaid A, Moon MC, Harding GE and Zahradka P: Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol 292: C919-C926, 2007
82. Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA and Sodek J: Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 184: 118-130, 2000
83. Shinohara ML, Lu L, Bu J, Werneck MB, Kobayashi KS, Glimcher LH and Cantor H: Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 7: 498-506, 2006
84. Chen R, Crispin DA, Pan S, Hawley S, McIntosh MW, May D, Anton-Culver H, Ziogas A, Bronner MP and Brentnall TA: Pilot study of blood biomarker candidates for detection of pancreatic cancer. Pancreas 39: 981-988, 2010
85. Fedarko NS, Jain A, Karadag A, Van Eman MR and Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060-4066, 2001
86. Collins AL, Rock J, Malhotra L, Frankel WL and Bloomston M: Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann Surg Oncol 19: 2673-2678, 2012
87. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ and Cantor H: Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287: 860-864, 2000
88. Chan SC, Tekari A, Benneker LM, Heini PF and Gantenbein B: Osteogenic differentiation of bone marrow stromal cells is hindered by the presence of intervertebral disc cells. Arthritis Res Ther 18: 29, 2015
89. Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M and Kundu GC: Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS One 8: e69116, 2013
90. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH and Yang PC: Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23: 953-964, 2005
91. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY and Sun HC: High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26: 2707-2716, 2008
92. Wai PY, Guo L, Gao C, Mi Z, Guo H and Kuo PC: Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery 140: 132-140, 2006
93. Sato K, Iwai A, Nakayama Y, Morimoto J, Takada A, Maruyama M, Kida H, Uede T and Miyazaki T: Osteopontin is critical to determine symptom severity of influenza through the regulation of NK cell population. Biochem Biophys Res Commun 417: 274-279, 2012
94. Collighan RJ and Griffin M: Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids 36: 659-670, 2009
95. He B, Mirza M and Weber GF: An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25: 2192-2202, 2006
96. Shen H and Weber GF: The osteopontin-c splice junction is important for anchorage-independent growth. Mol Carcinog 53: 480-487, 2014
97. Shi Z, Wang B, Chihanga T, Kennedy MA and Weber GF: Energy metabolism during anchorage-independence. Induction by osteopontin-c. PLoS One 9: e105675, 2014
98. Sivakumar S and Niranjali Devaraj S: Tertiary structure prediction and identification of druggable pocket in the cancer biomarker-osteopontin-c. J Diabetes Metab Disord 13: 13, 2014
99. Mi Z, Oliver T, Guo H, Gao C and Kuo PC: Thrombin-cleaved COOH(-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res 67: 4088-4097, 2007
100. Chimparlee N, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, Payungporn S, Poovorawan Y and Tangkijvanich P: Diagnostic and prognostic roles of serum osteopontin and osteopontin promoter polymorphisms in hepatitis B-related hepatocellular carcinoma. Asian Pac J Cancer Prev 16: 7211-7217, 2015
101. Sharma A, Hong S, Singh R and Jang J: Single-walled carbon nanotube based transparent immunosensor for detection of a prostate cancer biomarker osteopontin. Anal Chim Acta 869: 68-73, 2015
102. Faria M, Halquist MS, Yuan M, Mylott W Jr, Jenkins RG and Karnes HT: Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using capillary microflow LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 1001: 156-168, 2015
103. Meirinho SG, Dias LG, Peres AM and Rodrigues LR: Development of an electrochemical RNA-aptasensor to detect human osteopontin. Biosens Bioelectron 71: 332-341, 2015
104. Chen H, Mei Q, Jia S, Koh K, Wang K and Liu X: High specific detection of osteopontin using a three-dimensional copolymer layer support based on electrochemical impedance spectroscopy. Analyst (Lond) 139: 4476-4481, 2014